Cited by 500Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Open access

Kodumudi, Krithika N., Woan, Karrune, Gilvary, Danielle L., Sahakian, Eva, Wei, Sheng, Djeu, Julie Y.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-0733PMC PMC3874864

Open this paper in CoChat — free account

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0733

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,258
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Show all 42 references

Sorted by citations

Items 201–300 of 499

Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs
Martin, K., Schreiner, J., & Zippelius, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00501 · Cited by 46
Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
Leary, A. F., Genestie, C., Blanc‐Durand, F., Gouy, S., Dunant, A., Maulard, A., Drusch, F., Cheaib, B., Michels, J., Bentivegna, E., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02670-0 · Cited by 45
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives
Ibáñez-Vea, M., Zuazo, M., Gato, M., Arasanz, H., Fernández-Hinojal, G., Escors, D., & Kochan, G. T. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0492-4 · Cited by 45
Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 45
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond
Migali, C., Milano, M., Trapani, D., Criscitiello, C., Espósito, A., Locatelli, M., Minchella, I., & Curigliano, G. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016658423 · Cited by 44
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy
Kamran, N., Chandran, M., Lowenstein, P. R., & Castro, M. G. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.008 · Cited by 44
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
Santegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. C., van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465166 · Cited by 44
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
Dorhoi, A., Kotzé, L. A., Berzofsky, J. A., Sui, Y., Gabrilovich, D. I., Garg, A., Hafner, R., Khader, S. A., Schaible, U. E., Kaufmann, S. H. E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136288 · Cited by 44
Prostate cancer immunotherapy
Mitsogiannis, I. C., Tzelves, L. I., Dellis, A., Issa, H., Papatsoris, A., & Moussa, M. J. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2027904 · Cited by 46
Beyond immunosuppressive effects: dual roles of myeloid-derived suppressor cells in bone-related diseases
Ling, Z., Yang, C. H., Tan, J., Dou, C., & Chen, Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03966-9 · Cited by 43
SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells
Pengam, S., Durand, J., Usal, C., Gauttier, V., Dilek, N., Martinet, B., Daguin, V., Mary, C., Thépenier, V., Teppaz, G., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15497 · Cited by 42
The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer
Luker, A. J., Graham, L., Smith, T. M., Camarena, C., Zellner, M. P., Gilmer, J.-J. S., Damle, S., Conrad, D. H., Bear, H. D., & Martin, R. (2020) · BMC Immunology · doi:10.1186/s12865-020-0337-5 · Cited by 42
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma
Cai, M., Wang, Y., Ma, H., Li, Y., & Xu, Z. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102840 · Cited by 44
Aging tumour cells to cure cancer: “pro-senescence” therapy for cancer
Calcinotto, A., & Alimonti, A. (2017) · Swiss Medical Weekly · doi:10.57187/smw.2017.14367 · Cited by 42
Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory
Luo, W., Yang, G., Luo, W., Cao, Z., Liu, Y., Qiu, J., Chen, G., You, L., Zhao, F., Zheng, L., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1147-9 · Cited by 41
Personalized peptide vaccines and their relation to other therapies in urological cancer
Kimura, T., Egawa, S., & Uemura, H. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.77 · Cited by 40
Oxaliplatin regulates myeloid‐derived suppressor cell‐mediated immunosuppression via downregulation of nuclear factor‐κB signaling
Kim, N., & Kim, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1878 · Cited by 40
Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Zhao, J., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000710 · Cited by 40
Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment
Accogli, T., Bruchard, M., & Végran, F. (2021) · Cancers · doi:10.3390/cancers13030373 · Cited by 43
Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin, S. F. (2012) · PubMed · Cited by 39
Nanomedicine and cancer immunotherapy – targeting immunosuppressive cells
Andón, F. T., & Alonso, M. J. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1073295 · Cited by 39
Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin
Zhou, J., Donatelli, S. S., Gilvary, D. L., Tejera, M. M., Eksioglu, E. A., Chen, X., Coppola, D., Sheng, W., & Djeu, J. Y. (2016) · Scientific Reports · doi:10.1038/srep29521 · Cited by 38
Self-citation
Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications
Khairallah, A. S., Genestie, C., Auguste, A., & Leary, A. F. (2017) · International Journal of Cancer · doi:10.1002/ijc.31200 · Cited by 38
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 40
Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling
Jha, S. K., Chung, J. Y., Pangeni, R., Choi, H. S., Subedi, L., Kweon, S., Choi, J. U., Byun, Y., Kim, Y., & Park, J. W. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.067 · Cited by 38
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 39
Targeting myeloid regulatory cells in cancer by chemotherapeutic agents
Naiditch, H., Shurin, M. R., & Shurin, G. V. (2011) · Immunologic Research · doi:10.1007/s12026-011-8213-2 · Cited by 37
Tumor-Induced Myeloid-Derived Suppressor Cells
Sanctis, F. D., Bronte, V., & Ugel, S. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0016-2015 · Cited by 37
Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
de Coaña, Y. P., Masucci, G. V., Hansson, J., & Kiessling, R. W. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1570-7 · Cited by 36
Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
Dufait, I., Valckenborgh, E. V., Menu, E., Escors, D., Ridder, M. D., & Breckpot, K. (2016) · Oncotarget · doi:10.18632/oncotarget.8311 · Cited by 36
Rational combination immunotherapeutic approaches for effective cancer treatment
Phung, C. D., Nguyen, H. T., Tran, T. H., Choi, H., Yong, C. S., & Kim, J. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.020 · Cited by 35
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
Watanabe, J., Saito, M., Horimoto, Y., & Nakamoto, S. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05626-1 · Cited by 35
Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment
Li, Y., He, H., Jihu, R., Zhou, J., Zeng, R., & Yan, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.698532 · Cited by 35
Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice
Zhang, J., Pan, S., Chen, J., Li, H., Dong, J., Sun, Q., Jin, H., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.819405 · Cited by 39
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Qureshi, S., Chan, N., George, M. A., Ganesan, S., Toppmeyer, D., & Omene, C. O. (2022) · Biomarker Insights · doi:10.1177/11772719221078774 · Cited by 36
Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
Lim, H.-K., Kim, K. M., Jeong, S., Choi, E. K., & Jung, J. (2016) · Integrative Cancer Therapies · doi:10.1177/1534735416645184 · Cited by 35
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy
Pandya, A. D., Jäger, E., Fam, S. B., Höcherl, A., Jäger, A., Sincari, V., Nyström, B., Štěpánek, P., Skotland, T., Sandvig, K., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s208938 · Cited by 35
Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy
Roliński, J., & Hus, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.865094 · Cited by 34
Contribution of the immune system to the chemotherapeutic response
McDonnell, A. M., Nowak, A. K., & Lake, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0246-z · Cited by 34
l -arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice
Cao, Y. Q., Wang, Q., Du, Y., Liu, F., Zhang, Y., Feng, Y., & Jin, F. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.002 · Cited by 34
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida, D. V. P., Fong, L. H., Rettig, M. B., & Autio, K. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_278853 · Cited by 34
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer
Liu, W., Zhang, L., Xiu, Z., Guo, J., Wang, L., Zhou, Y., Jiao, Y., Sun, M., & Cai, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s255491 · Cited by 34
The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells
Sánchez-León, M. L., Jiménez‐Cortegana, C., Cabrera, G., Vermeulen, E. M., de la Cruz‐Merino, L., & Sánchez‐Margalet, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1050484 · Cited by 34
Taxanes as radiosensitizers
Golden, E. B., Formenti, S. C., & Schiff, P. B. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000055 · Cited by 34
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
Lang, X., Wang, X., Han, M., & Guo, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455213 · Cited by 36
A Novel Cinnamide YLT26 Induces Breast Cancer Cells ApoptosisviaROS-Mitochondrial Apoptotic Pathwayin Vitroand Inhibits Lung Metastasisin Vivo
Xiong, Y., Ye, T., Wang, M., Xia, Y., Wang, N., Song, X., Wang, F., Liu, L., Zhu, Y., Yang, F., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000366385 · Cited by 33
Role of Myeloid-Derived Suppressor Cells in Tumor Immunotherapy
Martin, F., Apétoh, L., & Ghiringhelli, F. (2011) · Immunotherapy · doi:10.2217/imt.11.154 · Cited by 33
Myeloid‑derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma
Tomiyama, T., Itoh, S., Iseda, N., Toshida, K., Morinaga, A., Yugawa, K., Kosai‐Fujimoto, Y., Tomino, T., Kurihara, T., Nagao, Y., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13213 · Cited by 33
A Biomimetic Nanogel System Restores Macrophage Phagocytosis for Magnetic Resonance Imaging‐Guided Synergistic Chemoimmunotherapy of Breast Cancer
Li, L., Gao, Y., Zhang, Y., Yang, R., Ouyang, Z., Guo, R., Yu, H., Shi, X., & Cao, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300967 · Cited by 33
Circulating CD 14+ HLA ‐ DR ‐/low myeloid‐derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft‐versus‐host disease
Yin, J., Wang, C., Huang, M., Mao, X., Zhou, J., & Zhang, Y. (2016) · Cancer Medicine · doi:10.1002/cam4.688 · Cited by 33
Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system
Zhang, L., Su, X., Ye, J. S., Wang, Y. Y., Guan, Z., & Yin, Y. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0039-8 · Cited by 32
Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells
Kuczma, M., Ding, Z., & Zhou, G. (2016) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016017507 · Cited by 32
The role of myeloid-derived suppressor cells in chronic infectious diseases and the current methodology available for their study
Peñaloza, H. F., Alvarez, D., Muñoz‐Durango, N., Schultz, B. M., González, P. A., Kalergis, A. M., & Bueno, S. M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0618-233r · Cited by 32
Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β
Pradhan, A. K., Maji, S., Bhoopathi, P., Talukdar, S., Mannangatti, P., Guo, C., Wang, X., Colon-Cartagena, L., Idowu, M. O., Landry, J. W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103180118 · Cited by 32
Targeting myeloid-derived suppressor cells for cancer therapy
Tang, H., Li, H., & Sun, Z. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0806 · Cited by 32
Daunorubicin conjugated with alpha-fetoprotein selectively eliminates myeloid-derived suppressor cells (MDSCs) and inhibits experimental tumor growth
Belyaev, N. N., Abdolla, N., Perfilyeva, Y. V., Ostapchuk, Y. O., Krasnoshtanov, V. K., Kali, A., & Tleulieva, R. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2067-y · Cited by 32
Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells
Pei, Q., Pan, J., Zhu, H., Ding, X., Liu, W., Lv, Y., Zou, X., & Luo, H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2013.12.022 · Cited by 31
Analysis of radiotherapy‑induced alteration of CD8+ T cells and PD‑L1 expression in patients with uterine cervical squamous cell carcinoma
Mori, Y., Sato, H., Kumazawa, T., Permata, T. B. M., Yoshimoto, Y., Murata, K., Noda, S., Kaminuma, T., Ando, K., Oike, T., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12707 · Cited by 31
The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge
Li, C., Cang, W., Gu, Y. L., Chen, L., & Xiang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1195476 · Cited by 31
Innate Immune Cells in Breast Cancer – From Villains to Heroes?
Kees, T., & Egeblad, M. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9224-2 · Cited by 31
Drafting the proteome landscape of myeloid‐derived suppressor cells
Gato, M., Blanco‐Luquin, I., Zudaire, M., de Morentin, X. M., Pérez‐Valderrama, E., Zabaleta, A., Kochan, G. T., Escors, D., Fernández‐Irigoyen, J., & Santamaría, E. (2015) · PROTEOMICS · doi:10.1002/pmic.201500229 · Cited by 33
PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review
Wang, J. C. C., & Sun, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105837 · Cited by 31
Early-phase Treatment by Low-dose 5-Fluorouracil or Primary Tumor Resection Inhibits MDSC-mediated Lung Metastasis Formation.
Otsubo, D., Yamashita, K., Fujita, M., Nishi, M., Kimura, Y., Hasegawa, H., Suzuki, S., & Kakeji, Y. (2015) · PubMed · Cited by 30
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
Noguchi, M., Arai, G., Egawa, S., Οhyama, C., Naito, S., Matsumoto, K., Uemura, H., Nakagawa, M., Nasu, Y., Eto, M., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02498-8 · Cited by 30
Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer
Kim, R., & Kin, T. (2021) · Cancers · doi:10.3390/cancers13194756 · Cited by 30
Progress in Nanocarriers Codelivery System to Enhance the Anticancer Effect of Photodynamic Therapy
Yang, Y., Lin, K., & Li, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111951 · Cited by 30
Immune checkpoint inhibitors in advanced nonsmall cell lung cancer
Hélissey, C., Champiat, S., & Soria, J. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000167 · Cited by 31
Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
Rajkumari, S., Singh, J., Agrawal, U., & Agrawal, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112949 · Cited by 28
Cancer Immunotherapy
Ito, F., & Chang, A. E. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.005 · Cited by 28
High-molecular weight star conjugates containing docetaxel with high anti-tumor activity and low systemic toxicity in vivo
Etrych, T., Strohalm, J., Šírová, M., Tomalová, B., Rossmann, P., Řı́hová, B., Ulbrich, K., & Kovář, M. (2014) · Polymer Chemistry · doi:10.1039/c4py01120a · Cited by 28
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Bryant, G., Wang, L., & Mulholland, D. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071542 · Cited by 30
Impact of systemic therapy on circulating leukocyte populations in patients with metastatic breast cancer
Larsson, A.-M., Roxå, A., Leandersson, K., & Bergenfelz, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-49943-y · Cited by 29
Myeloid-derived suppressor cells and their role in gynecological malignancies
Mabuchi, S., Yokoi, E., Komura, N., & Kimura, T. (2018) · Tumor Biology · doi:10.1177/1010428318776485 · Cited by 29
The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer
Dou, T., Li, J., Zhang, Y., Pei, W., Zhang, B., Wang, B., Wang, Y., & Jia, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368687 · Cited by 29
Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy
Morel, D., Robert, C., Nikos Paragios, A., Grégoire, V., & Deutsch, É. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3632 · Cited by 29
Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome
Tiraboschi, C., Gentilini, L. D., Velazquez, C., Corapi, E., Jaworski, F. M., Garcia, J. D. G., Rondón, Y., Chauchereau, A., Laderach, D. J., & Compagno, D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001535 · Cited by 27
Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups
Burkert, S. C., Shurin, G. V., White, D. L., He, X., Kapralov, A. A., Kagan, V. E., Shurin, M. R., & Star, A. (2018) · Nanoscale · doi:10.1039/c8nr04437f · Cited by 26
Macrophages at the crossroads of anticancer strategies
Marchesi, F. (2019) · Frontiers in bioscience · doi:10.2741/4779 · Cited by 26
Enhancement of CD8+ T‐Cell‐Mediated Tumor Immunotherapy via Magnetic Hyperthermia
Zhang, Y., Gao, X., Yan, B., Wen, N., Lee, W. S. V., Liang, X., & Liu, X. (2021) · ChemMedChem · doi:10.1002/cmdc.202100656 · Cited by 27
Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
Doloff, J. C., Chen, C.-S., & Waxman, D. J. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-158 · Cited by 26
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy
Reardon, D. A., Gilbert, M. R., Wick, W., & Liau, L. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov178 · Cited by 27
Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers
Mabuchi, S., & Sasano, T. (2021) · Cells · doi:10.3390/cells10051073 · Cited by 29
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy
Deng, X., Shen, Y., Yi, M., Zhang, C. H., Zhao, B., Zhong, G., WeiyangLou, Xue, D., Leng, Q., Ding, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28768 · Cited by 25
Identification of Caspase-6 as a New Regulator of Alternatively Activated Macrophages
Yao, Y., Shi, Q., Chen, B., Wang, Q., Li, X., Li, L., Huang, Y., Ji, J., & Shen, P. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.717868 · Cited by 25
Tumor-Infiltrating Lymphocytes as a Feasible Adjuvant Immunotherapy for Osteosarcoma with a Poor Response to Neoadjuvant Chemotherapy
Shi, J., Li, M., & Yang, R. (2020) · Immunotherapy · doi:10.2217/imt-2020-0107 · Cited by 25
Galectin-3 contributes to cisplatin-induced myeloid derived suppressor cells (MDSCs) recruitment in Lewis lung cancer-bearing mice
Wang, T., Chu, Z., Lin, H., Jiang, J., Zhou, X., & Liang, X. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3276-5 · Cited by 25
Jacalin-Activated Macrophages Exhibit an Antitumor Phenotype
Polli, C. D., Ruas, L. P., Veronez, L. C., Geraldino, T. H., de Morais, F. R., Roque‐Barreira, M. C., & Pereira-da-Silva, G. (2016) · BioMed Research International · doi:10.1155/2016/2925657 · Cited by 24
Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model
Zhang, H., Almuqbil, R. M., Alhudaithi, S. S., Sunbul, F. S., & da Rocha, S. R. P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120350 · Cited by 24
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs
Zhang, X., Sun, S., Miao, Y., Yuan, Y., Zhao, W., Li, H., Wei, X., Huang, C., Hu, X., Wang, B., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04248-y · Cited by 24
Micellar nanoparticles inhibit breast cancer and pulmonary metastasis by modulating the recruitment and depletion of myeloid-derived suppressor cells
Lu, Z., Liu, H., Ma, L., Ren, K., He, Z., Li, M., & He, Q. S. (2022) · Nanoscale · doi:10.1039/d2nr03880c · Cited by 24
ICAM-1-decorated extracellular vesicles loaded with miR-146a and Glut1 drive immunomodulation and hinder tumor progression in a murine model of breast cancer
Duarte‐Sanmiguel, S., Salazar‐Puerta, A. I., Panic, A., Dodd, D. J., Francis, C., Alzate‐Correa, D., Ortega‐Pineda, L., Lemmerman, L. R., Rincon‐Benavides, M. A., Dathathreya, K., et al. (2023) · Biomaterials Science · doi:10.1039/d3bm00573a · Cited by 24
The role of myeloid-derived suppressor cells in hematologic malignancies
Gunes, E. G., Rosen, S. T., & Querfeld, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000662 · Cited by 24
Polysaccharide isolated from Grifola frondosa eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cells responses
Li, X., Ruan, Q., Yang, W., Tian, H., Wu, N., Qadir, J., Wang, J., Hu, H., Liu, Y., Cai, M., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.85276 · Cited by 23
Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study
Saito, H., Fushida, S., Miyashita, T., Oyama, K., Yamaguchi, T., Tsukada, T., Kinoshita, J., Tajima, H., Ninomiya, I., & Ohta, T. (2017) · BMC Cancer · doi:10.1186/s12885-017-3279-4 · Cited by 23
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy
Takahashi, H., Sakakura, K., Mito, I., Ida, S., & Chikamatsu, K. (2016) · Cancer Science · doi:10.1111/cas.12976 · Cited by 23
A vascular disrupting agent overcomes tumor multidrug resistance by skewing macrophage polarity toward the M1 phenotype
Lei, X., Chen, M., Li, X., Huang, M., Nie, Q., Ma, N., Chen, H., Xu, N., Ye, W., & Zhang, D. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.016 · Cited by 22
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
Heath, B. R., Michmerhuizen, N. L., Donnelly, C. R., Sansanaphongpricha, K., Sun, D., Brenner, J. C., & Lei, Y. L. (2019) · Journal of Dental Research · doi:10.1177/0022034519864112 · Cited by 22
Extracellular vesicles: the “Trojan Horse” within breast cancer host microenvironments
Kang, Y., Meng, L., Bai, S., & Li, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02358-y · Cited by 21
Immunotherapeutic options on the horizon in breast cancer treatment
van Rooijen, J. M., Stutvoet, T. S., Schröder, C. P., & de Vries, E. G. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.09.003 · Cited by 21
Myeloid-derived suppressor cells (MDSC): Another player in the orchestra
Gimeno, R., & Barquinero, J. (2011) · Inmunología · doi:10.1016/s0213-9626(11)70015-4 · Cited by 21

Authors: Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
Affiliations: Moffitt Cancer Center (US)
Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
Corresponding author: Djeu, Julie Y.
ORCID: Kodumudi, Krithika N.
Woan, Karrune
Sahakian, Eva
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-09-14
Volume: 16
Issue: 18
Pages: 4583-4594
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-0733
PMC: PMC3874864
OpenAlex: W2143994426
Cited by: 500
References: 42
Citations by year: 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
FWCI: 10.74
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (T32CA115308)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
MeSH terms: Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks